Therefore, identifying a noninvasive tool to monitor HER2 expression levels in vivo might contribute to improve the correct localization of HER2-positive tumor lesions, monitor the response to HER2-targeted therapy, and improve the selection of BC patients who may benefit from multiple antibody–drug conjugates. This evidence concerns the gene ERBB2 and neoplasm.